nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—ALB—acquired immunodeficiency syndrome	0.215	1	CbGaD
Clomipramine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0191	0.0363	CbGbCtD
Clomipramine—ALB—Saquinavir—acquired immunodeficiency syndrome	0.019	0.0361	CbGbCtD
Clomipramine—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0182	0.0346	CbGbCtD
Clomipramine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.018	0.0341	CbGbCtD
Clomipramine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0177	0.0335	CbGbCtD
Clomipramine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0166	0.0315	CbGbCtD
Clomipramine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0166	0.0315	CbGbCtD
Clomipramine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0163	0.0308	CbGbCtD
Clomipramine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0163	0.0308	CbGbCtD
Clomipramine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.015	0.0285	CbGbCtD
Clomipramine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0146	0.0276	CbGbCtD
Clomipramine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0145	0.0275	CbGbCtD
Clomipramine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0141	0.0266	CbGbCtD
Clomipramine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0137	0.0259	CbGbCtD
Clomipramine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0137	0.0259	CbGbCtD
Clomipramine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0136	0.0258	CbGbCtD
Clomipramine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0131	0.0249	CbGbCtD
Clomipramine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0126	0.0239	CbGbCtD
Clomipramine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0124	0.0235	CbGbCtD
Clomipramine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0124	0.0235	CbGbCtD
Clomipramine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0123	0.0234	CbGbCtD
Clomipramine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0123	0.0234	CbGbCtD
Clomipramine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0118	0.0224	CbGbCtD
Clomipramine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0114	0.0216	CbGbCtD
Clomipramine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0113	0.0215	CbGbCtD
Clomipramine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.011	0.0209	CbGbCtD
Clomipramine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0107	0.0202	CbGbCtD
Clomipramine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0104	0.0197	CbGbCtD
Clomipramine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00995	0.0189	CbGbCtD
Clomipramine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00995	0.0189	CbGbCtD
Clomipramine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00954	0.0181	CbGbCtD
Clomipramine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00938	0.0178	CbGbCtD
Clomipramine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00938	0.0178	CbGbCtD
Clomipramine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00925	0.0175	CbGbCtD
Clomipramine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0087	0.0165	CbGbCtD
Clomipramine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0087	0.0165	CbGbCtD
Clomipramine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00787	0.0149	CbGbCtD
Clomipramine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00787	0.0149	CbGbCtD
Clomipramine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00738	0.014	CbGbCtD
Clomipramine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00679	0.0129	CbGbCtD
Clomipramine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00659	0.0125	CbGbCtD
Clomipramine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00596	0.0113	CbGbCtD
Clomipramine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00596	0.0113	CbGbCtD
Clomipramine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00572	0.0108	CbGbCtD
Clomipramine—GSTP1—blood plasma—acquired immunodeficiency syndrome	0.00147	0.0338	CbGeAlD
Clomipramine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00143	0.0328	CbGeAlD
Clomipramine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00123	0.0281	CbGeAlD
Clomipramine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00102	0.0233	CbGeAlD
Clomipramine—HRH2—skin of body—acquired immunodeficiency syndrome	0.000984	0.0226	CbGeAlD
Clomipramine—HTR2A—nerve—acquired immunodeficiency syndrome	0.000858	0.0197	CbGeAlD
Clomipramine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00083	0.019	CbGeAlD
Clomipramine—GSTP1—retina—acquired immunodeficiency syndrome	0.000807	0.0185	CbGeAlD
Clomipramine—HRH2—digestive system—acquired immunodeficiency syndrome	0.000787	0.0181	CbGeAlD
Clomipramine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.000763	0.0175	CbGeAlD
Clomipramine—HRH2—blood—acquired immunodeficiency syndrome	0.00075	0.0172	CbGeAlD
Clomipramine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.000731	0.0168	CbGeAlD
Clomipramine—GSTP1—skin of body—acquired immunodeficiency syndrome	0.000708	0.0163	CbGeAlD
Clomipramine—HTR6—nervous system—acquired immunodeficiency syndrome	0.000666	0.0153	CbGeAlD
Clomipramine—HRH2—lung—acquired immunodeficiency syndrome	0.000657	0.0151	CbGeAlD
Clomipramine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.000649	0.0149	CbGeAlD
Clomipramine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.000641	0.0147	CbGeAlD
Clomipramine—HRH2—nervous system—acquired immunodeficiency syndrome	0.000609	0.014	CbGeAlD
Clomipramine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000601	0.0138	CbGeAlD
Clomipramine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000591	0.0136	CbGeAlD
Clomipramine—HRH2—central nervous system—acquired immunodeficiency syndrome	0.000586	0.0134	CbGeAlD
Clomipramine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000584	0.0134	CbGeAlD
Clomipramine—GSTP1—lymphoid tissue—acquired immunodeficiency syndrome	0.000574	0.0132	CbGeAlD
Clomipramine—GSTP1—digestive system—acquired immunodeficiency syndrome	0.000567	0.013	CbGeAlD
Clomipramine—GSTP1—blood—acquired immunodeficiency syndrome	0.00054	0.0124	CbGeAlD
Clomipramine—GSTP1—bone marrow—acquired immunodeficiency syndrome	0.000522	0.012	CbGeAlD
Clomipramine—GSTP1—spinal cord—acquired immunodeficiency syndrome	0.00052	0.0119	CbGeAlD
Clomipramine—HTR6—brain—acquired immunodeficiency syndrome	0.000509	0.0117	CbGeAlD
Clomipramine—GSTP1—vagina—acquired immunodeficiency syndrome	0.0005	0.0115	CbGeAlD
Clomipramine—GSTP1—lung—acquired immunodeficiency syndrome	0.000473	0.0109	CbGeAlD
Clomipramine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000472	0.0108	CbGeAlD
Clomipramine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000467	0.0107	CbGeAlD
Clomipramine—HRH2—brain—acquired immunodeficiency syndrome	0.000465	0.0107	CbGeAlD
Clomipramine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000457	0.0105	CbGeAlD
Clomipramine—HRH2—lymph node—acquired immunodeficiency syndrome	0.00045	0.0103	CbGeAlD
Clomipramine—SLC6A4—blood—acquired immunodeficiency syndrome	0.000449	0.0103	CbGeAlD
Clomipramine—HTR2B—blood—acquired immunodeficiency syndrome	0.000445	0.0102	CbGeAlD
Clomipramine—GSTP1—nervous system—acquired immunodeficiency syndrome	0.000438	0.0101	CbGeAlD
Clomipramine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.000433	0.00993	CbGeAlD
Clomipramine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000425	0.00976	CbGeAlD
Clomipramine—GSTP1—central nervous system—acquired immunodeficiency syndrome	0.000422	0.00968	CbGeAlD
Clomipramine—HTR2B—vagina—acquired immunodeficiency syndrome	0.000413	0.00947	CbGeAlD
Clomipramine—SLC6A4—lung—acquired immunodeficiency syndrome	0.000394	0.00904	CbGeAlD
Clomipramine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000391	0.00897	CbGeAlD
Clomipramine—HTR2B—lung—acquired immunodeficiency syndrome	0.00039	0.00896	CbGeAlD
Clomipramine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000385	0.00883	CbGeAlD
Clomipramine—CYP2C19—blood—acquired immunodeficiency syndrome	0.000372	0.00854	CbGeAlD
Clomipramine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.00037	0.0085	CbGeAlD
Clomipramine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000365	0.00837	CbGeAlD
Clomipramine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000361	0.00829	CbGeAlD
Clomipramine—HTR2A—retina—acquired immunodeficiency syndrome	0.000355	0.00815	CbGeAlD
Clomipramine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000351	0.00806	CbGeAlD
Clomipramine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000348	0.00798	CbGeAlD
Clomipramine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000347	0.00796	CbGeAlD
Clomipramine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000345	0.00792	CbGeAlD
Clomipramine—GSTP1—brain—acquired immunodeficiency syndrome	0.000335	0.00769	CbGeAlD
Clomipramine—GSTP1—lymph node—acquired immunodeficiency syndrome	0.000324	0.00743	CbGeAlD
Clomipramine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000321	0.00737	CbGeAlD
Clomipramine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000319	0.00732	CbGeAlD
Clomipramine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000309	0.00709	CbGeAlD
Clomipramine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000304	0.00698	CbGeAlD
Clomipramine—HTR2C—brain—acquired immunodeficiency syndrome	0.000294	0.00675	CbGeAlD
Clomipramine—ALB—brain—acquired immunodeficiency syndrome	0.000287	0.00658	CbGeAlD
Clomipramine—ADRA2A—blood—acquired immunodeficiency syndrome	0.00028	0.00642	CbGeAlD
Clomipramine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000279	0.0064	CbGeAlD
Clomipramine—ALB—lymph node—acquired immunodeficiency syndrome	0.000277	0.00636	CbGeAlD
Clomipramine—HTR2B—brain—acquired immunodeficiency syndrome	0.000276	0.00634	CbGeAlD
Clomipramine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000269	0.00618	CbGeAlD
Clomipramine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000267	0.00612	CbGeAlD
Clomipramine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000267	0.00612	CbGeAlD
Clomipramine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000259	0.00595	CbGeAlD
Clomipramine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.00025	0.00573	CbGeAlD
Clomipramine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000245	0.00563	CbGeAlD
Clomipramine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000245	0.00562	CbGeAlD
Clomipramine—HTR2A—blood—acquired immunodeficiency syndrome	0.000238	0.00546	CbGeAlD
Clomipramine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000237	0.00544	CbGeAlD
Clomipramine—ABCB1—retina—acquired immunodeficiency syndrome	0.000233	0.00534	CbGeAlD
Clomipramine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000231	0.0053	CbGeAlD
Clomipramine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000229	0.00526	CbGeAlD
Clomipramine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000227	0.00522	CbGeAlD
Clomipramine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000227	0.00521	CbGeAlD
Clomipramine—HTR2A—vagina—acquired immunodeficiency syndrome	0.00022	0.00506	CbGeAlD
Clomipramine—CYP3A4—blood—acquired immunodeficiency syndrome	0.00022	0.00505	CbGeAlD
Clomipramine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000219	0.00501	CbGeAlD
Clomipramine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000217	0.00497	CbGeAlD
Clomipramine—HTR2A—lung—acquired immunodeficiency syndrome	0.000208	0.00478	CbGeAlD
Clomipramine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000193	0.00443	CbGeAlD
Clomipramine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000186	0.00426	CbGeAlD
Clomipramine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000179	0.0041	CbGeAlD
Clomipramine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000176	0.00403	CbGeAlD
Clomipramine—ADRA2A—brain—acquired immunodeficiency syndrome	0.000173	0.00398	CbGeAlD
Clomipramine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000172	0.00395	CbGeAlD
Clomipramine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000169	0.00388	CbGeAlD
Clomipramine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000168	0.00385	CbGeAlD
Clomipramine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000166	0.0038	CbGeAlD
Clomipramine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000164	0.00375	CbGeAlD
Clomipramine—ABCB1—blood—acquired immunodeficiency syndrome	0.000156	0.00357	CbGeAlD
Clomipramine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000151	0.00346	CbGeAlD
Clomipramine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.00015	0.00344	CbGeAlD
Clomipramine—HTR2A—brain—acquired immunodeficiency syndrome	0.000148	0.00338	CbGeAlD
Clomipramine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000144	0.00331	CbGeAlD
Clomipramine—ABCB1—lung—acquired immunodeficiency syndrome	0.000137	0.00313	CbGeAlD
Clomipramine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000134	0.00308	CbGeAlD
Clomipramine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000126	0.0029	CbGeAlD
Clomipramine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000122	0.00279	CbGeAlD
Clomipramine—ABCB1—brain—acquired immunodeficiency syndrome	9.67e-05	0.00222	CbGeAlD
Clomipramine—ABCB1—lymph node—acquired immunodeficiency syndrome	9.34e-05	0.00214	CbGeAlD
Clomipramine—Acepromazine—ALB—acquired immunodeficiency syndrome	6.84e-05	0.189	CrCbGaD
Clomipramine—Thioproperazine—ALB—acquired immunodeficiency syndrome	6.68e-05	0.185	CrCbGaD
Clomipramine—Anaemia—Lamivudine—acquired immunodeficiency syndrome	6.64e-05	0.000324	CcSEcCtD
Clomipramine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	6.64e-05	0.000324	CcSEcCtD
Clomipramine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	6.62e-05	0.000323	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.61e-05	0.000323	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.59e-05	0.000322	CcSEcCtD
Clomipramine—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.59e-05	0.000321	CcSEcCtD
Clomipramine—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.59e-05	0.000321	CcSEcCtD
Clomipramine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	6.58e-05	0.000321	CcSEcCtD
Clomipramine—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.58e-05	0.000321	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.57e-05	0.000321	CcSEcCtD
Clomipramine—Pipotiazine—ALB—acquired immunodeficiency syndrome	6.57e-05	0.182	CrCbGaD
Clomipramine—Cough—Saquinavir—acquired immunodeficiency syndrome	6.57e-05	0.00032	CcSEcCtD
Clomipramine—Pain—Indinavir—acquired immunodeficiency syndrome	6.53e-05	0.000319	CcSEcCtD
Clomipramine—Constipation—Indinavir—acquired immunodeficiency syndrome	6.53e-05	0.000319	CcSEcCtD
Clomipramine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.53e-05	0.000318	CcSEcCtD
Clomipramine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.52e-05	0.000318	CcSEcCtD
Clomipramine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.52e-05	0.000318	CcSEcCtD
Clomipramine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	6.51e-05	0.000318	CcSEcCtD
Clomipramine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6.5e-05	0.000317	CcSEcCtD
Clomipramine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	6.49e-05	0.000317	CcSEcCtD
Clomipramine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	6.49e-05	0.000317	CcSEcCtD
Clomipramine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	6.49e-05	0.000316	CcSEcCtD
Clomipramine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	6.48e-05	0.000316	CcSEcCtD
Clomipramine—Malaise—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000316	CcSEcCtD
Clomipramine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.47e-05	0.000315	CcSEcCtD
Clomipramine—Nausea—Didanosine—acquired immunodeficiency syndrome	6.46e-05	0.000315	CcSEcCtD
Clomipramine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.45e-05	0.000315	CcSEcCtD
Clomipramine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.45e-05	0.000315	CcSEcCtD
Clomipramine—Syncope—Lamivudine—acquired immunodeficiency syndrome	6.44e-05	0.000314	CcSEcCtD
Clomipramine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.44e-05	0.000314	CcSEcCtD
Clomipramine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.43e-05	0.000314	CcSEcCtD
Clomipramine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000314	CcSEcCtD
Clomipramine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.42e-05	0.000313	CcSEcCtD
Clomipramine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.41e-05	0.000313	CcSEcCtD
Clomipramine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.41e-05	0.000313	CcSEcCtD
Clomipramine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.41e-05	0.000313	CcSEcCtD
Clomipramine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	6.39e-05	0.000312	CcSEcCtD
Clomipramine—Oedema—Ritonavir—acquired immunodeficiency syndrome	6.39e-05	0.000311	CcSEcCtD
Clomipramine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	6.37e-05	0.000311	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	6.37e-05	0.00031	CcSEcCtD
Clomipramine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	6.35e-05	0.00031	CcSEcCtD
Clomipramine—Discomfort—Saquinavir—acquired immunodeficiency syndrome	6.33e-05	0.000309	CcSEcCtD
Clomipramine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	6.31e-05	0.000308	CcSEcCtD
Clomipramine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	6.29e-05	0.000307	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	6.29e-05	0.000307	CcSEcCtD
Clomipramine—Shock—Ritonavir—acquired immunodeficiency syndrome	6.28e-05	0.000306	CcSEcCtD
Clomipramine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	6.27e-05	0.000306	CcSEcCtD
Clomipramine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	6.27e-05	0.000306	CcSEcCtD
Clomipramine—Cough—Lamivudine—acquired immunodeficiency syndrome	6.27e-05	0.000306	CcSEcCtD
Clomipramine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	6.27e-05	0.000306	CcSEcCtD
Clomipramine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.000305	CcSEcCtD
Clomipramine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	6.25e-05	0.000305	CcSEcCtD
Clomipramine—Dizziness—Stavudine—acquired immunodeficiency syndrome	6.25e-05	0.000305	CcSEcCtD
Clomipramine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	6.25e-05	0.000305	CcSEcCtD
Clomipramine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	6.25e-05	0.000305	CcSEcCtD
Clomipramine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	6.23e-05	0.000304	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	6.23e-05	0.000304	CcSEcCtD
Clomipramine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000304	CcSEcCtD
Clomipramine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	6.22e-05	0.000303	CcSEcCtD
Clomipramine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	6.22e-05	0.000303	CcSEcCtD
Clomipramine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	6.2e-05	0.000302	CcSEcCtD
Clomipramine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	6.2e-05	0.000302	CcSEcCtD
Clomipramine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	6.2e-05	0.000302	CcSEcCtD
Clomipramine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	6.17e-05	0.000301	CcSEcCtD
Clomipramine—Pain—Efavirenz—acquired immunodeficiency syndrome	6.17e-05	0.000301	CcSEcCtD
Clomipramine—Constipation—Efavirenz—acquired immunodeficiency syndrome	6.17e-05	0.000301	CcSEcCtD
Clomipramine—Rash—Nevirapine—acquired immunodeficiency syndrome	6.17e-05	0.000301	CcSEcCtD
Clomipramine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	6.16e-05	0.000301	CcSEcCtD
Clomipramine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	6.16e-05	0.0003	CcSEcCtD
Clomipramine—Dizziness—Abacavir—acquired immunodeficiency syndrome	6.16e-05	0.0003	CcSEcCtD
Clomipramine—Oedema—Saquinavir—acquired immunodeficiency syndrome	6.15e-05	0.0003	CcSEcCtD
Clomipramine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	6.14e-05	0.000299	CcSEcCtD
Clomipramine—Headache—Nevirapine—acquired immunodeficiency syndrome	6.13e-05	0.000299	CcSEcCtD
Clomipramine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000298	CcSEcCtD
Clomipramine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000298	CcSEcCtD
Clomipramine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000298	CcSEcCtD
Clomipramine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	6.09e-05	0.000297	CcSEcCtD
Clomipramine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	6.09e-05	0.000297	CcSEcCtD
Clomipramine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	6.08e-05	0.000296	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000296	CcSEcCtD
Clomipramine—Urticaria—Indinavir—acquired immunodeficiency syndrome	6.07e-05	0.000296	CcSEcCtD
Clomipramine—Shock—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000295	CcSEcCtD
Clomipramine—Discomfort—Lamivudine—acquired immunodeficiency syndrome	6.04e-05	0.000295	CcSEcCtD
Clomipramine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	6.04e-05	0.000294	CcSEcCtD
Clomipramine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	6.04e-05	0.000294	CcSEcCtD
Clomipramine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000294	CcSEcCtD
Clomipramine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	6.03e-05	0.000294	CcSEcCtD
Clomipramine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	6.02e-05	0.000293	CcSEcCtD
Clomipramine—Vomiting—Stavudine—acquired immunodeficiency syndrome	6.01e-05	0.000293	CcSEcCtD
Clomipramine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	6e-05	0.000293	CcSEcCtD
Clomipramine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.98e-05	0.000292	CcSEcCtD
Clomipramine—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.98e-05	0.000291	CcSEcCtD
Clomipramine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.97e-05	0.000291	CcSEcCtD
Clomipramine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.97e-05	0.000291	CcSEcCtD
Clomipramine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.97e-05	0.000291	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.96e-05	0.000291	CcSEcCtD
Clomipramine—Rash—Stavudine—acquired immunodeficiency syndrome	5.96e-05	0.000291	CcSEcCtD
Clomipramine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.95e-05	0.00029	CcSEcCtD
Clomipramine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.95e-05	0.00029	CcSEcCtD
Clomipramine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.95e-05	0.00029	CcSEcCtD
Clomipramine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.94e-05	0.00029	CcSEcCtD
Clomipramine—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.94e-05	0.00029	CcSEcCtD
Clomipramine—Headache—Stavudine—acquired immunodeficiency syndrome	5.92e-05	0.000289	CcSEcCtD
Clomipramine—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.92e-05	0.000289	CcSEcCtD
Clomipramine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.91e-05	0.000288	CcSEcCtD
Clomipramine—Pain—Delavirdine—acquired immunodeficiency syndrome	5.9e-05	0.000288	CcSEcCtD
Clomipramine—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.9e-05	0.000288	CcSEcCtD
Clomipramine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000288	CcSEcCtD
Clomipramine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.89e-05	0.000287	CcSEcCtD
Clomipramine—Rash—Abacavir—acquired immunodeficiency syndrome	5.87e-05	0.000286	CcSEcCtD
Clomipramine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.86e-05	0.000286	CcSEcCtD
Clomipramine—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000286	CcSEcCtD
Clomipramine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.86e-05	0.000286	CcSEcCtD
Clomipramine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	5.86e-05	0.000286	CcSEcCtD
Clomipramine—Headache—Abacavir—acquired immunodeficiency syndrome	5.83e-05	0.000284	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.000284	CcSEcCtD
Clomipramine—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.81e-05	0.000283	CcSEcCtD
Clomipramine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.81e-05	0.000283	CcSEcCtD
Clomipramine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.78e-05	0.000282	CcSEcCtD
Clomipramine—Shock—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000281	CcSEcCtD
Clomipramine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.00028	CcSEcCtD
Clomipramine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.74e-05	0.00028	CcSEcCtD
Clomipramine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.74e-05	0.00028	CcSEcCtD
Clomipramine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.73e-05	0.00028	CcSEcCtD
Clomipramine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.73e-05	0.00028	CcSEcCtD
Clomipramine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.7e-05	0.000278	CcSEcCtD
Clomipramine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.7e-05	0.000278	CcSEcCtD
Clomipramine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.69e-05	0.000278	CcSEcCtD
Clomipramine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.69e-05	0.000278	CcSEcCtD
Clomipramine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000277	CcSEcCtD
Clomipramine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.68e-05	0.000277	CcSEcCtD
Clomipramine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.67e-05	0.000276	CcSEcCtD
Clomipramine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.65e-05	0.000275	CcSEcCtD
Clomipramine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.63e-05	0.000275	CcSEcCtD
Clomipramine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.63e-05	0.000274	CcSEcCtD
Clomipramine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000274	CcSEcCtD
Clomipramine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.62e-05	0.000274	CcSEcCtD
Clomipramine—Nausea—Stavudine—acquired immunodeficiency syndrome	5.61e-05	0.000274	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000273	CcSEcCtD
Clomipramine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.59e-05	0.000273	CcSEcCtD
Clomipramine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.56e-05	0.000271	CcSEcCtD
Clomipramine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000271	CcSEcCtD
Clomipramine—Nausea—Abacavir—acquired immunodeficiency syndrome	5.53e-05	0.00027	CcSEcCtD
Clomipramine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.52e-05	0.000269	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.51e-05	0.000269	CcSEcCtD
Clomipramine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.51e-05	0.000268	CcSEcCtD
Clomipramine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.49e-05	0.000268	CcSEcCtD
Clomipramine—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.48e-05	0.000267	CcSEcCtD
Clomipramine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.48e-05	0.000267	CcSEcCtD
Clomipramine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.48e-05	0.000267	CcSEcCtD
Clomipramine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000266	CcSEcCtD
Clomipramine—Pain—Ritonavir—acquired immunodeficiency syndrome	5.46e-05	0.000266	CcSEcCtD
Clomipramine—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.46e-05	0.000266	CcSEcCtD
Clomipramine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.46e-05	0.000266	CcSEcCtD
Clomipramine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.46e-05	0.000266	CcSEcCtD
Clomipramine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.43e-05	0.000265	CcSEcCtD
Clomipramine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000264	CcSEcCtD
Clomipramine—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.4e-05	0.000264	CcSEcCtD
Clomipramine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.000261	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.34e-05	0.00026	CcSEcCtD
Clomipramine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.32e-05	0.000259	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.31e-05	0.000259	CcSEcCtD
Clomipramine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.3e-05	0.000259	CcSEcCtD
Clomipramine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.3e-05	0.000258	CcSEcCtD
Clomipramine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	5.26e-05	0.000257	CcSEcCtD
Clomipramine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000257	CcSEcCtD
Clomipramine—Pain—Saquinavir—acquired immunodeficiency syndrome	5.26e-05	0.000256	CcSEcCtD
Clomipramine—Constipation—Saquinavir—acquired immunodeficiency syndrome	5.26e-05	0.000256	CcSEcCtD
Clomipramine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	5.23e-05	0.000255	CcSEcCtD
Clomipramine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	5.23e-05	0.000255	CcSEcCtD
Clomipramine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	5.22e-05	0.000255	CcSEcCtD
Clomipramine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000255	CcSEcCtD
Clomipramine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000254	CcSEcCtD
Clomipramine—Rash—Zidovudine—acquired immunodeficiency syndrome	5.18e-05	0.000253	CcSEcCtD
Clomipramine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	5.18e-05	0.000253	CcSEcCtD
Clomipramine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	5.17e-05	0.000252	CcSEcCtD
Clomipramine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000252	CcSEcCtD
Clomipramine—Headache—Zidovudine—acquired immunodeficiency syndrome	5.15e-05	0.000251	CcSEcCtD
Clomipramine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	5.11e-05	0.000249	CcSEcCtD
Clomipramine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000249	CcSEcCtD
Clomipramine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	5.09e-05	0.000248	CcSEcCtD
Clomipramine—Nortriptyline—ALB—acquired immunodeficiency syndrome	5.08e-05	0.141	CrCbGaD
Clomipramine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	5.07e-05	0.000247	CcSEcCtD
Clomipramine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000247	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	5.06e-05	0.000247	CcSEcCtD
Clomipramine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	5.05e-05	0.000247	CcSEcCtD
Clomipramine—Dizziness—Indinavir—acquired immunodeficiency syndrome	5.05e-05	0.000246	CcSEcCtD
Clomipramine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	5.05e-05	0.000246	CcSEcCtD
Clomipramine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	5.05e-05	0.000246	CcSEcCtD
Clomipramine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	5.03e-05	0.000245	CcSEcCtD
Clomipramine—Constipation—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000245	CcSEcCtD
Clomipramine—Pain—Lamivudine—acquired immunodeficiency syndrome	5.01e-05	0.000245	CcSEcCtD
Clomipramine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.95e-05	0.000242	CcSEcCtD
Clomipramine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.94e-05	0.000241	CcSEcCtD
Clomipramine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.89e-05	0.000238	CcSEcCtD
Clomipramine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.88e-05	0.000238	CcSEcCtD
Clomipramine—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.88e-05	0.000238	CcSEcCtD
Clomipramine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.86e-05	0.000237	CcSEcCtD
Clomipramine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.86e-05	0.000237	CcSEcCtD
Clomipramine—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.86e-05	0.000237	CcSEcCtD
Clomipramine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000236	CcSEcCtD
Clomipramine—Rash—Indinavir—acquired immunodeficiency syndrome	4.82e-05	0.000235	CcSEcCtD
Clomipramine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.81e-05	0.000235	CcSEcCtD
Clomipramine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000234	CcSEcCtD
Clomipramine—Headache—Indinavir—acquired immunodeficiency syndrome	4.78e-05	0.000233	CcSEcCtD
Clomipramine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.77e-05	0.000233	CcSEcCtD
Clomipramine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.72e-05	0.00023	CcSEcCtD
Clomipramine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.7e-05	0.000229	CcSEcCtD
Clomipramine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.66e-05	0.000227	CcSEcCtD
Clomipramine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.63e-05	0.000226	CcSEcCtD
Clomipramine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.63e-05	0.000226	CcSEcCtD
Clomipramine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.59e-05	0.000224	CcSEcCtD
Clomipramine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.58e-05	0.000223	CcSEcCtD
Clomipramine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.57e-05	0.000223	CcSEcCtD
Clomipramine—Rash—Efavirenz—acquired immunodeficiency syndrome	4.55e-05	0.000222	CcSEcCtD
Clomipramine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.55e-05	0.000222	CcSEcCtD
Clomipramine—Nausea—Indinavir—acquired immunodeficiency syndrome	4.54e-05	0.000221	CcSEcCtD
Clomipramine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.53e-05	0.000221	CcSEcCtD
Clomipramine—Headache—Efavirenz—acquired immunodeficiency syndrome	4.52e-05	0.00022	CcSEcCtD
Clomipramine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.52e-05	0.00022	CcSEcCtD
Clomipramine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.41e-05	0.000215	CcSEcCtD
Clomipramine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.39e-05	0.000214	CcSEcCtD
Clomipramine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.37e-05	0.000213	CcSEcCtD
Clomipramine—Rash—Delavirdine—acquired immunodeficiency syndrome	4.35e-05	0.000212	CcSEcCtD
Clomipramine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.35e-05	0.000212	CcSEcCtD
Clomipramine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.35e-05	0.000212	CcSEcCtD
Clomipramine—Headache—Delavirdine—acquired immunodeficiency syndrome	4.33e-05	0.000211	CcSEcCtD
Clomipramine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.32e-05	0.000211	CcSEcCtD
Clomipramine—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.29e-05	0.000209	CcSEcCtD
Clomipramine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4.22e-05	0.000206	CcSEcCtD
Clomipramine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	4.21e-05	0.000205	CcSEcCtD
Clomipramine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	4.2e-05	0.000205	CcSEcCtD
Clomipramine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	4.15e-05	0.000202	CcSEcCtD
Clomipramine—Nausea—Delavirdine—acquired immunodeficiency syndrome	4.1e-05	0.0002	CcSEcCtD
Clomipramine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	4.06e-05	0.000198	CcSEcCtD
Clomipramine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	4.06e-05	0.000198	CcSEcCtD
Clomipramine—Rash—Ritonavir—acquired immunodeficiency syndrome	4.03e-05	0.000196	CcSEcCtD
Clomipramine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	4.02e-05	0.000196	CcSEcCtD
Clomipramine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	4.01e-05	0.000196	CcSEcCtD
Clomipramine—Headache—Ritonavir—acquired immunodeficiency syndrome	4e-05	0.000195	CcSEcCtD
Clomipramine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.91e-05	0.000191	CcSEcCtD
Clomipramine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.88e-05	0.000189	CcSEcCtD
Clomipramine—Rash—Saquinavir—acquired immunodeficiency syndrome	3.87e-05	0.000189	CcSEcCtD
Clomipramine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.87e-05	0.000189	CcSEcCtD
Clomipramine—Headache—Saquinavir—acquired immunodeficiency syndrome	3.85e-05	0.000188	CcSEcCtD
Clomipramine—Diazepam—ALB—acquired immunodeficiency syndrome	3.84e-05	0.106	CrCbGaD
Clomipramine—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.79e-05	0.000185	CcSEcCtD
Clomipramine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.73e-05	0.000182	CcSEcCtD
Clomipramine—Rash—Lamivudine—acquired immunodeficiency syndrome	3.7e-05	0.00018	CcSEcCtD
Clomipramine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.69e-05	0.00018	CcSEcCtD
Clomipramine—Headache—Lamivudine—acquired immunodeficiency syndrome	3.67e-05	0.000179	CcSEcCtD
Clomipramine—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.65e-05	0.000178	CcSEcCtD
Clomipramine—Chlorpromazine—ALB—acquired immunodeficiency syndrome	3.56e-05	0.0987	CrCbGaD
Clomipramine—Amitriptyline—ALB—acquired immunodeficiency syndrome	3.52e-05	0.0976	CrCbGaD
Clomipramine—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.00017	CcSEcCtD
Clomipramine—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.77e-05	0.00213	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.77e-05	0.00213	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.75e-05	0.0021	CbGpPWpGaD
Clomipramine—HTR6—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.73e-05	0.00208	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.73e-05	0.00207	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.72e-05	0.00206	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.71e-05	0.00206	CbGpPWpGaD
Clomipramine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.71e-05	0.00206	CbGpPWpGaD
Clomipramine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.69e-05	0.00204	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.69e-05	0.00203	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.69e-05	0.00203	CbGpPWpGaD
Clomipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.67e-05	0.00201	CbGpPWpGaD
Clomipramine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.002	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.64e-05	0.00197	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.61e-05	0.00194	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.61e-05	0.00194	CbGpPWpGaD
Clomipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.61e-05	0.00194	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	1.59e-05	0.00191	CbGpPWpGaD
Clomipramine—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.58e-05	0.0019	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.58e-05	0.00189	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.57e-05	0.00189	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.56e-05	0.00187	CbGpPWpGaD
Clomipramine—GSTP1—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.54e-05	0.00185	CbGpPWpGaD
Clomipramine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.00185	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.54e-05	0.00185	CbGpPWpGaD
Clomipramine—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	1.52e-05	0.00183	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.52e-05	0.00183	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.52e-05	0.00182	CbGpPWpGaD
Clomipramine—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	1.51e-05	0.00182	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.00181	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	1.49e-05	0.00179	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.47e-05	0.00176	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.47e-05	0.00176	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.47e-05	0.00176	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.46e-05	0.00175	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.46e-05	0.00175	CbGpPWpGaD
Clomipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.45e-05	0.00174	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.43e-05	0.00172	CbGpPWpGaD
Clomipramine—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.43e-05	0.00172	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.00171	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.42e-05	0.00171	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.42e-05	0.00171	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.42e-05	0.00171	CbGpPWpGaD
Clomipramine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.42e-05	0.00171	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.0017	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.41e-05	0.0017	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.4e-05	0.00168	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.39e-05	0.00167	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.39e-05	0.00167	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.38e-05	0.00166	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.38e-05	0.00165	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.33e-05	0.0016	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.33e-05	0.0016	CbGpPWpGaD
Clomipramine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.32e-05	0.00159	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.32e-05	0.00158	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.3e-05	0.00156	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.3e-05	0.00156	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.3e-05	0.00156	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.29e-05	0.00155	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.29e-05	0.00155	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.28e-05	0.00154	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.00153	CbGpPWpGaD
Clomipramine—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.27e-05	0.00153	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	1.27e-05	0.00152	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.26e-05	0.00152	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.26e-05	0.00151	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.26e-05	0.00151	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.24e-05	0.00149	CbGpPWpGaD
Clomipramine—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	1.23e-05	0.00148	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.23e-05	0.00147	CbGpPWpGaD
Clomipramine—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	1.21e-05	0.00145	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.2e-05	0.00144	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.18e-05	0.00142	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.18e-05	0.00142	CbGpPWpGaD
Clomipramine—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	1.18e-05	0.00141	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.17e-05	0.00141	CbGpPWpGaD
Clomipramine—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.17e-05	0.0014	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.16e-05	0.00139	CbGpPWpGaD
Clomipramine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.16e-05	0.00139	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.12e-05	0.00135	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.12e-05	0.00134	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.12e-05	0.00134	CbGpPWpGaD
Clomipramine—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.11e-05	0.00133	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.0013	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.07e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.07e-05	0.00129	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.07e-05	0.00128	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.07e-05	0.00128	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.06e-05	0.00127	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	1.06e-05	0.00127	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.05e-05	0.00126	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.05e-05	0.00126	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.03e-05	0.00124	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.01e-05	0.00122	CbGpPWpGaD
Clomipramine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.01e-05	0.00121	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.00121	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	9.99e-06	0.0012	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.97e-06	0.0012	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.97e-06	0.0012	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	9.91e-06	0.00119	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.89e-06	0.00119	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.84e-06	0.00118	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	9.83e-06	0.00118	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.77e-06	0.00117	CbGpPWpGaD
Clomipramine—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	9.77e-06	0.00117	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.75e-06	0.00117	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.73e-06	0.00117	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	9.71e-06	0.00117	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.7e-06	0.00117	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.69e-06	0.00116	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.69e-06	0.00116	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.53e-06	0.00114	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.53e-06	0.00114	CbGpPWpGaD
Clomipramine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.5e-06	0.00114	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.31e-06	0.00112	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.31e-06	0.00112	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.11e-06	0.00109	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.11e-06	0.00109	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.99e-06	0.00108	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.99e-06	0.00108	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	8.97e-06	0.00108	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.91e-06	0.00107	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.87e-06	0.00107	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.85e-06	0.00106	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.85e-06	0.00106	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.82e-06	0.00106	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.8e-06	0.00106	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	8.76e-06	0.00105	CbGpPWpGaD
Clomipramine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.71e-06	0.00105	CbGpPWpGaD
Clomipramine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	8.6e-06	0.00103	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.47e-06	0.00102	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.47e-06	0.00102	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.42e-06	0.00101	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.29e-06	0.000996	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.29e-06	0.000996	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.27e-06	0.000994	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.27e-06	0.000994	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	8.25e-06	0.000992	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	8.22e-06	0.000988	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.21e-06	0.000986	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.13e-06	0.000977	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.09e-06	0.000973	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.01e-06	0.000962	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.98e-06	0.000959	CbGpPWpGaD
Clomipramine—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	7.95e-06	0.000956	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.86e-06	0.000945	CbGpPWpGaD
Clomipramine—GSTP1—Metabolism—ALB—acquired immunodeficiency syndrome	7.8e-06	0.000937	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	7.76e-06	0.000932	CbGpPWpGaD
Clomipramine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	7.66e-06	0.000921	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.66e-06	0.00092	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.64e-06	0.000918	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.64e-06	0.000918	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.58e-06	0.000911	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.53e-06	0.000905	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.53e-06	0.000905	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.47e-06	0.000897	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.42e-06	0.000892	CbGpPWpGaD
Clomipramine—HRH2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.36e-06	0.000884	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.25e-06	0.000871	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.19e-06	0.000864	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.14e-06	0.000858	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	6.99e-06	0.00084	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.98e-06	0.000838	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.98e-06	0.000838	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.93e-06	0.000833	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.83e-06	0.000821	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.83e-06	0.00082	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.68e-06	0.000803	CbGpPWpGaD
Clomipramine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.66e-06	0.0008	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.62e-06	0.000795	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.53e-06	0.000785	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	6.41e-06	0.00077	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.35e-06	0.000762	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.31e-06	0.000758	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.29e-06	0.000756	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.25e-06	0.00075	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.21e-06	0.000746	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.2e-06	0.000745	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.99e-06	0.000719	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.81e-06	0.000699	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.75e-06	0.000691	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.73e-06	0.000688	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.73e-06	0.000688	CbGpPWpGaD
Clomipramine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.7e-06	0.000685	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.68e-06	0.000683	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.67e-06	0.000681	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.64e-06	0.000678	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.64e-06	0.000678	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.63e-06	0.000676	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.63e-06	0.000676	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.4e-06	0.000648	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.31e-06	0.000638	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.24e-06	0.000629	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.23e-06	0.000628	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.23e-06	0.000628	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.2e-06	0.000625	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	5.19e-06	0.000624	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.16e-06	0.00062	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.15e-06	0.000619	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.12e-06	0.000616	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.89e-06	0.000587	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.89e-06	0.000587	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.78e-06	0.000575	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.73e-06	0.000568	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.68e-06	0.000562	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.45e-06	0.000534	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.45e-06	0.000534	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.28e-06	0.000515	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.22e-06	0.000507	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.16e-06	0.000499	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.13e-06	0.000496	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	4.1e-06	0.000493	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.95e-06	0.000474	CbGpPWpGaD
Clomipramine—HRH2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.93e-06	0.000472	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.86e-06	0.000464	CbGpPWpGaD
Clomipramine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.83e-06	0.000461	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.77e-06	0.000453	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.72e-06	0.000447	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.66e-06	0.00044	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.61e-06	0.000434	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.38e-06	0.000407	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.35e-06	0.000403	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.33e-06	0.0004	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.28e-06	0.000394	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.28e-06	0.000394	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.22e-06	0.000387	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.05e-06	0.000366	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.03e-06	0.000364	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.01e-06	0.000362	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.98e-06	0.000358	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.76e-06	0.000332	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.75e-06	0.00033	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	2.6e-06	0.000312	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.32e-06	0.000279	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.23e-06	0.000268	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.22e-06	0.000267	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.94e-06	0.000233	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.93e-06	0.000231	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.84e-06	0.000221	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.8e-06	0.000216	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.78e-06	0.000214	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.76e-06	0.000212	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.75e-06	0.000211	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.69e-06	0.000203	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.62e-06	0.000195	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.43e-06	0.000172	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.31e-06	0.000157	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.14e-06	0.000137	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.11e-06	0.000133	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.04e-06	0.000124	CbGpPWpGaD
